NOBLEOAK LIFE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.65 AUD | 0.00% |
|
0.00% | -0.60% |
| 28/02 | NobleOak Life Shares Add 7% Despite 55% Plunge in Fiscal H1 Profit | MT |
| 28/02 | Transcript : NobleOak Life Limited, H1 2024 Earnings Call, Feb 28, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.18 for the current year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company sustains low margins.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.60% | 92.95M | - | ||
| +3.05% | 95.15B | B | ||
| +1.78% | 94.71B | B- | ||
| -20.65% | 77.24B | B+ | ||
| +18.68% | 74.93B | D+ | ||
| +6.69% | 30.04B | B | ||
| +18.06% | 27.87B | B | ||
| +4.32% | 26.97B | A | ||
| -1.21% | 16.99B | C+ | ||
| -9.10% | 15.16B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- NOL Stock
- Ratings NobleOak Life Limited
